Calcium antagonists and endothelial function focus on nitric oxide and endothelin

Cardiovascular Drugs and Therapy

Volumn 10, Issue 4, 1996, Pages 439-446

  Godfraind, Théophile ^a   Salomone, Salvatore ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Calcium antagonists; Calcium channel blockers; Diltiazem; Endothelin; Human coronary artery; Human coronary vein; Hypertension; Isradipine; Lacidipine; Nisoldipine; Nitric oxide; Verapamil

Indexed keywords

CALCIUM ANTAGONIST; CALCIUM CHANNEL; ENDOTHELIN; LACIDIPINE; NITRIC OXIDE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; GENE EXPRESSION; HEART MUSCLE CONTRACTILITY; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; SALT INTAKE; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CORONARY VESSELS; DIHYDROPYRIDINES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HUMANS; NITRIC OXIDE; RATS; RNA, MESSENGER; SODIUM CHLORIDE, DIETARY;

EID: 0029910783     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00051108     Document Type: Article

References (44)

1. Godfraind T, Kaba A. Blockade or reversal of contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. Br J Pharmacol 1969;36:549-560.
2. Godfraind T, Miller RC, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986;38:321-416.
3. Fleckenstein A, ed. Calcium Antagonism in Heart and Smooth Muscle. Experimental Facts and Therapeutic Prospects. New York: John Wiley, 1983.
4. Godfraind T. Calcium antagonists and vasodilatation. Pharmacol Ther 1994;64:37-75.
5. Moncada S, Plamer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
6. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
7. Glossmann H, Lübbecke F, Mewes R, Derry DR, Hosmann F. Calcium channels: Direct identification with radioligand binding studies. Trends Pharmacol Sci 1982;3:431-437.
8. Spedding M. Calcium antagonist subgroups. Trends Pharmacol Sci 1985;6:109-114.
9. 2+ channels. Trends Pharmacol Sci 1989;10:349-354.
10. 2+ channel function and drug action. Trends Pharmacol Sci 1995;16:43-49.
11. Spedding M, Paoletti R. Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol Rev 1992;44:363-376.
12. Hosey MM, Lazdunski M. Calcium channels: Molecular pharmacology, structure and regulation. J Memb Biol 1988; 104:81-105.
13. McKenna E, Koch WJ, Slish DF, Schwartz A. Toward an understanding of the dihydropyridine-sensitive calcium channel. Biochem Pharmacol 1990;39:1145-1150.
14. 1 subunit of intestinal smooth muscle and other tissues. Eur J Biochem 1994;222:195-202.
15. Salomone S, Silva LM, Morel N, Godfraind T. Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery. Naunyn Schmiedebergs Arch Pharmacol 1996, in press.
16. 2+ signal and contraction in rat aorta. Br J Pharmacol 1995; 114:1731-1737.
17. 2+ antagonist Ro 40-5967 on endothelium-dependent responses of isolated arteries. J Cardiovasc Pharmacol 1994;23:869-876.
18. Szabo C, Thiemermann C, Vane J. Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Biochem Biophys Res Commun 1993;196:825-830.
19. Yanagisawa M, Masaki T. Molecular biology and biochemistry of the endothelins. Trends Pharmacol Sci 1989;10: 374-378.
20. Balligand JL, Godfraind T. Effect of nisoldipine on the contractions evoked by endothelin-1 in human isolated distal and proximal coronary arteries and veins. J Cardiovase Pharmacol 1994;24:618-625.
21. Godfraind T. Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol 1993;110:1201-1205.
22. Hartter E, Woloszczuk W. Radioimmunoassay of endothelin. Lancet 1989;1:909.
23. Davenport AP, Ashby MJ, Easton P, et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci 1990;78:261-264.
24. Luscher TF. Endothelin: Key to coronary vasospasm? Circulation 1990;83:701-703.
25. McFadden EP, Clarke JG, Davies GJ, Kaski JC, Haider AW, Maseri A. Effect of introcoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991;324:648-654.
26. Houston DS, Shepherd JT, Vanhoutte PM. Aggregating human platelets cause direct contraction and endotheliumdependent relaxation in isolated canine coronary arteries. J Clin Invest 1986;78:539-544.
27. Schiffrin EL. Endothelin: Potential role in hypertension and vascular hypertrophy. Hypertension 1995;25:1135-1143.
28. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;368:703-710.
29. Hoffman A, Grossman E, Abassi ZA, Keiser HR. Renal endothelin and hypertension. Nature 1994;372:50.
30. Suzuki T, Hoshi H, Mitsui Y. Endothelin stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium. FEBS Lett 1990;268:149-151.
31. Ito H, Hirata H, Hiroe M, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;69:209-215.
32. Campese VM. Salt sensitivity in hypertension: Renal and cardiovascular implications. Hypertension 1994;23:531-550.
33. Beil AH, Schmieder RE, Messerli FH. Salt intake, blood pressure and cardiovascular structure. Cardiovasc Drugs Ther 1994;8:425-432.
34. Feron O, Salomone S, Godfraind T. Inhibition by lacidipine of salt-dependent cardiac hypertrophy and endothelin gene expression in stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 1995;210:219-224.
35. Battistini B, Chailler P, D'Orléans-Juste P, Brière N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993;14:385-399.
36. Lariviere R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993;21:294-300.
37. Ito H, Hirata Y, Adachi S, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993;92:398-403.
38. Sung C-P, Arleth AJ, Storer BL, Ohlstein EH. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther 1994;271:429-437.
39. + feeding in stroke-prone hypertensive rats. Hypertension 1990;15:318-326.
40. Yamashita Y, Takata Y, Takishita S, Kimura Y, Fujishima M. Enhancement of brain renin-angiotensin system induced by long-term salt loading in spontaneously hypertensive rats. J Hypertens 1986;4:S361-S363.
41. Feron O, Salomone S, Godfraind T. Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats. Br J Pharmacol 1996;118:659-664.
42. Grohe C, Nouskas J, Vetter H, Neyses L. Effects of nisoldipine on endothelin-1- and angiotensin II-induced immediate/early gene expression and protein synthesis in adult rat ventricular cardiomyocytes. J Cardiovasc Pharmacol 1994; 24:13-16.
43. Ziv I, Fleminger G, Djaldetti R, Achiron A, Melamed E, Sokolovsky M. Increased plama endothelin-1 in acute ischemic stroke. Stroke 1992;23:1014-1016.
44. Stanimirovic DB, Bertrand N, McCarron R, Uematsu S, Spatz M. Arachidonic acid release and permeability changes induced by endothelins in human cerebromicrovascular endothelium. Acta Neurochir Suppl Wien 1994;60:71-75.